請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78281完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤(TSAI-KUN LI) | |
| dc.contributor.author | Jia-Jun Huang | en |
| dc.contributor.author | 黃佳鈞 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:49:15Z | - |
| dc.date.available | 2025-08-18 | |
| dc.date.copyright | 2020-09-10 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-17 | |
| dc.identifier.citation | 1. de Mattos, B.R., et al., Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm, 2015. 2015: p. 493012. 2. Piovani, D., et al., Inflammatory bowel disease: estimates from the global burden of disease 2017 study. Aliment Pharmacol Ther, 2020. 51(2): p. 261-270. 3. Ng, S.C., et al., Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 2018. 390(10114): p. 2769-2778. 4. Yen, H.H., et al., Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest Res, 2019. 17(1): p. 54-62. 5. Landskron, G., et al., Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014. 2014: p. 149185. 6. Shrihari, T.G., Dual role of inflammatory mediators in cancer. Ecancermedicalscience, 2017. 11: p. 721. 7. Rialdi, A., et al., Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science, 2016. 352(6289): p. aad7993. 8. Wendorff, T.J., et al., The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol, 2012. 424(3-4): p. 109-24. 9. Yang, Y.C., et al., Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis. Antioxid Redox Signal, 2013. 18(10): p. 1129-40. 10. Ju, B.G., et al., A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science, 2006. 312(5781): p. 1798-802. 11. Pommier, Y., et al., Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol, 2016. 17(11): p. 703-721. 12. Brennan, C.A. and W.S. Garrett, Gut Microbiota, Inflammation, and Colorectal Cancer. Annu Rev Microbiol, 2016. 70: p. 395-411. 13. Ternes, D., et al., Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism? Trends Microbiol, 2020. 28(5): p. 401-423. 14. Bian, X., et al., Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. Front Microbiol, 2019. 10: p. 2259. 15. Parasuraman, S., R. Raveendran, and R. Kesavan, Blood sample collection in small laboratory animals. J Pharmacol Pharmacother, 2010. 1(2): p. 87-93. 16. Lee, S.H., Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res, 2015. 13(1): p. 11-8. 17. Cobo, E.R. and K. Chadee, Antimicrobial Human β-Defensins in the Colon and Their Role in Infectious and Non-Infectious Diseases. Pathogens, 2013. 2(1): p. 177-92. 18. Rodríguez-Perálvarez, M.L., et al., Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis, 2012. 18(10): p. 1864-71. 19. Koeninger, L., et al., Human β-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. Front Immunol, 2020. 11: p. 93. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78281 | - |
| dc.description.abstract | 發炎屬於形成腫瘤的標誌之一,慢性的發炎會提高癌症發生的可能性。直腸結腸癌是造成全球癌症死亡的主要原因之一,而像是發炎性腸道疾病(IBD)在全世界的發生率及盛行率逐年攀升,長期且復發性的發炎與腫瘤的形成高度相關。因此,我們對於發炎所導致的腫瘤發展相當感興趣。 先前實驗室發現,第二型拓樸異構酶β亞型(Top2β)參與了發炎過程中一氧化氮(NO)誘導的DNA損傷,並驗證了降低Top2β或抑制Top2β的表達可以減少基因組的不穩定性和腫瘤的發生。但是,我們也注意到VillinCre-Top2β小鼠的腫瘤大小受到影響。我們認為這可能是由於發炎細胞因子或腸道菌群的表現改變了微環境,因為Top2β已知在調節DNA轉錄中扮演重要的作用。我們的動物實驗結果顯示與WT小鼠相比,VillinCre-Top2β小鼠的發炎現象增加。然而在細胞實驗中,敲除Top2β會限制β-defensin在上皮細胞中的表達以及發炎細胞因子在免疫細胞及上皮細胞的表達。這種矛盾的結果可能是因為VillinCre-Top2β小鼠只剔除上皮細胞中的Top2β基因,導致上皮細胞在防禦感染性刺激方面的功能缺失。與動物實驗結果相似,VillinCre-Top2β小鼠的菌相似乎與大腸發炎和大腸癌更為相關。 根據上述結果,發炎反應調控腸道菌群和宿主之間的相互作用,並且在影響腫瘤的發展中有著重要的作用。我們的發現暗示了Top2β在發炎反應的調節作用,進一步探討其相關機制能為了解發炎相關的癌症疾病提供新的方向。 | zh_TW |
| dc.description.abstract | Inflammation is one of the hallmark of tumor formation. Chronic inflammation raises the possibility of developing cancer. Colorectal cancer is one of the top leading causes of cancer death worldwide. Moreover, colon inflammatory disease s such as IBD keep s high prevalence and incidence and is increased yearly. Long term and relapse inflammation is highly associated with tumor. Thus, we are interested in elucidating the mechanisms of the inflammation-related tumor development. Top2β is already known to have a crucial role in the regulation of DNA transcription. Our lab previously found that Top2β was involved in the nitric oxide-induced DNA damage during inflammation and validated that decrease Top2β or inhibit the expression of Top2β could reduce the genome instability and tumor initiation. However, we also noticed the tumor volume affected in VillinCre Top2β mice. This may due to the microenvironment changed by the expression of inflammatory cytokine or gut microbiota Our animal experiment s showed the increased inflammation in VillinCre-Top2β mice compared to WT mice. However in cell experiments, Top2β knockdown restricted the expression of β defensin in epithelial cell line and pro-inflammatory cytokine in both immune cell line and epithelial cell line. We speculate that VillinCre Top2β mice may only deplete Top2β in epithelial, lead to the defect of the epithelial function to defense infectious agents. Consistent with the animal results, the fecal microbiota of VillinCre-Top2β mice seems to more co-related to colon inflammation and colon cancer. From the above results, the inflammatory response is co-related to the interaction between gut microbiota and host and is important in tumor development. Our finding implied the regulatory role of Top2β, and the associated mechanism might give a new direction to treat the inflammation-related cancer disease. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:49:15Z (GMT). No. of bitstreams: 1 U0001-1008202016015500.pdf: 2956204 bytes, checksum: 58edb941637dd6fdf49dc070005a6879 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 口試委員審定書 I ACKNOWLEDGEMENTS II ABSTRACT III 中文摘要 V CONTENT VI INTRODUCTION 1 1 Chronic inflammation and colorectal cancer 1 2 Topoisomerase 3 2.1 Topoisomerase and Transcription 3 2.2 Topoisomerase II-mediated DNA double strand break and mutagenesis activated by nitric oxide during inflammation. 4 2.3 Topoisomerase IIβ-mediated DNA break and transcription 5 3 Inflammation-related colon cancer and gut microbiota 6 SPECIFIC AIM 9 MATERIALS and METHODS 10 RESULTS 15 1. Top2β had effects on tumor formation during inflammation. (by Tom Chang) 15 2. Top2 inhibitor ICRF-193 affected inflammatory gene expression in RAW26.7 cells. 15 3. Inflammatory cytokine expression was restricted in Top2β knockdown cells. 16 4. Knockdown Top2β in HT29 cells reduced the expression of IL-8 and had no impact on epithelial cells expressing tight junction protein. 17 5. Knockdown Top2β in SW480 cells decreased the inflammation response stimulated by LPS. 18 6. The induced colitis of VillinCre-Top2βf/f mice was more severe than WT mice during 2.5% DSS treatment. 19 7. Mice with Top2 inhibitor ICRF-193 became more sensitive to DSS treatment. 21 8. The gut microbiota of VillinCre-Top2βf/f mice was more related to colon cancer than WT mice in AOM-DSS model. 21 9. In acute DSS model, the microbiota of VillinCre-Top2βf/f mice showed more relation with colon inflammation than WT mice. 24 DISCUSSION 25 TABLES and FIGURES 29 Table 1. The sequences of primers used in RT-qPCR. 29 Figure 1. The VillinCre-Top2βf/f mice had lower tumor number and higher tumor volume. (by Tom Chang) 30 Figure 2. The effects caused by ICRF-193 in inflammatory cytokine gene expression. 31 Figure 3. RAW264.7 cells with Top2β knockdown restricted the expression of pro-inflammatory cytokine. 34 Figure 4. HT29 cells with Top2β knockdown decrease the expression of IL-8 and remain the expression of tight junction protein occludin when LPS treated. 36 Figure 5. Top2β knockdown in SW480 cells decreased the expression of inflammatory response gene during LPS treatment. 39 Figure 6. DSS-induced weight loss and shorten colon length were more severe in VillinCre-Top2βf/f mice than WT mice. 41 Figure 7. Elevated levels of F4/80 expression in the colon tissue of VillinCre-Top2β mice compared to WT mice during DSS treatment. (by Tom Chang) 43 Figure 8. Mice injected by ICRF-193 (Top2 inhibitor) showed no difference in disease activity but shorten the colon length compared to control mice. 45 Figure 9. The composition of fecal microbiota differed in WT and VillinCre-Top2βf/f mice after DSS treatment in the AOM+DSS model. 48 Figure 10. The profile of feces microbiota change after DSS treatment and had difference between WT and VillinCre-Top2β mice in the acute DSS model. 51 Figure 11. Intestinal cells with Top2β deficiency affected tumor development in mice with inflammatory intestine. 53 REFERENCES 54 | |
| dc.language.iso | en | |
| dc.subject | 腸道微環境 | zh_TW |
| dc.subject | 腸道發炎 | zh_TW |
| dc.subject | 第二型拓樸異構酶β亞型 | zh_TW |
| dc.subject | 大腸癌 | zh_TW |
| dc.subject | Top2β | en |
| dc.subject | Inflammation | en |
| dc.subject | colitis microenvironment | en |
| dc.subject | colorectal cancer | en |
| dc.title | 探討第二型拓樸異構酶β亞型在腸道發炎相關癌症的微環境調控中的參與角色 | zh_TW |
| dc.title | Investigate on the role of Topoisomerase II β on the regulation of colitis microenvironment leading to colon cancer formation | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 繆希椿(SHI-CHUEN MIAW),楊宏志(Hung-Chih Yang) | |
| dc.subject.keyword | 腸道發炎,第二型拓樸異構酶β亞型,大腸癌,腸道微環境, | zh_TW |
| dc.subject.keyword | Top2β,Inflammation,colitis microenvironment,colorectal cancer, | en |
| dc.relation.page | 56 | |
| dc.identifier.doi | 10.6342/NTU202002824 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-18 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2025-08-18 | - |
| 顯示於系所單位: | 微生物學科所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1008202016015500.pdf 未授權公開取用 | 2.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
